Mahindra & Mahindra's farm equipment sector reported a 22% decline in domestic sales and a 26% fall in exports for August 2015 compared to the same period last year, while its stock price has been declining and technical indicators suggest further downside; Sun Pharmaceutical completed an acquisition that expands its global opiates business; and Asian stock markets opened mixed on Wednesday following global market declines driven by concerns over China's economic slowdown.

1. SEBI Certified – Research Analyst www.choiceindia.com
Global View
India Update
Today’s Event/ Stock in News
Mahindra&Mahindra's(M&M)FarmEquipmentSector(FES),apartofthe$16.5billionMahindraGroup,hasreporteditssalesnumbersforAugust2015.
DomesticsalesinAugust2015stoodat10,751units,downby22%asagainst13,733unitsduringAugust2014.Thecompany'stotaltractorsales(domestic
+ exports) during August 2015 stood at 15,006 units, down by 22% as against 11,699 units for the same period last year. Exports for the month stood at
1273 units,registering afallof 26%.Mahindra &Mahindra (M&M)is theflagship company oftheMahindra Group,a multinational conglomerate based in
Mumbai,India.Amongstthevariousbusinessinterestsofitsparentgroup,thecompanyismainlyinvolvedintheautomobilemanufacturing.Itisoneofthe
leadingautocompaniesofIndia.
Technical Outlook : On daily chart, since last five days, prices have been trading below its strong support of 200 DMA (which stands at 1240
levels). Furthermore, stock has formed three black crows candlestick pattern on weekly chart, which again confirm for trend reversal and
downside move. Momentum indicator RSI reading is below 40 marks with negative crossover, which point out for weakness in the stock. So
fortradingprospective,onecouldSellintherangeof1177-1183 forthetargetof1155-1133 levels.
Sun Pharmaceutical Industries has begun the integration of its Opiates business in Australia following the successful completion of this
acquisition from GSK (announced in March 2015). This acquisition fortifies Sun Pharma's global position with two Opiates manufacturing
facilities in Port Fairy & Latrobe (both in Australia) complementing its current API manufacturing footprint globally. Sun Pharma now offers a
rich basket of Opiates product line in addition to a large API portfolio and dosage formulations covering a broad range of chronic and acute
prescription drugs. The acquisition also brings a specialized team to drive business growth. The Opiates acquisition allows Sun Pharma to
significantly expand its narcotics raw material (NRM) market share; enhance Opiate Alkaloids portfolio and depth in Global opiates market and
strengthen its strategic position in the global Opiates business. Sun Pharma is the world's fifth largest specialty generic pharmaceutical
company and India's top pharmaceutical company.
Technical Outlook: Thestockhasbeen trading inascending triangle formationfrom last 4monthsand taking supportoflower bandof triangle
at 850 levels. Prices aretrading above 200 DEMA whichalso acting as crucial supportlevels. The momentum indicator RSI hasremained above
40levelswhichindicatingthepossibilitiesofbouncebackintheprices. Sofortradingprospective,onecouldBuyintherangeof898-902forthe
targetof911-920 levels.
M&M
SUNPHARMA
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Morning Tea
02nd Sept 2015
Buy in the range of 898-902 with of SL 889 for the Target of 911-920
Sell in the range of 1177-1183 with of SL 1195 for the Target of 1155-1133
Havocreturned to Wall Street on Tuesday after abrief rest, withrenewed concernsaboutChina's economy pushingmajor indexes down almost 3 percent
andintensifying fearsofalong-termselloff.Majordata showedthepaceofgrowthintheUSmanufacturing sectorslowedlastmonthtoits weakestinover
two years.The weak data pushed oil prices down morethan 7 percent, ending three days of gains, and also reduced some investors' expectations thatthe
FederalReservewouldraiseinterestratesthismonth.Addingtothenervousness,InternationalMonetaryFundheadChristineLagardesaidglobaleconomic
growthwasnowlikelytobeweakerthanhadbeen expectedjustafewmonthsago.TheDowJones industrialaveragefell2.84 percentto endat16,058.35
whiletheS&P500.SPXlost2.96percentto1,913.85points.TheNasdaqCompositedropped2.94percentto4,636.11.
Asian shares, meanwhile, opened mixed on Wednesday morning with Mainland shares leading losses, tracking offshore losses driven by
persisting concerns over the health of China's economy. Global worries and lower than expected GDP and core sector data hit Dalal Street on
Tuesday. Equity benchmark indices crashed more than 2 percent on fears of slowdown in China, the world's second largest economy. All
sectors ended in the red with banks being worst hit. The Shanghai Composite index extended losses to ease 2.76 % to 3081.69, Hang Seng
index opened down 1.44 % to 20855.59, Japan's benchmark Nikkei 225 index up by 0.79% to 18309.43, South Korea's Kospi index edged
marginally down by -0.48% to 1905.12 level. The Indian equity market is likely to open flat to positive today.

2. SEBI Certified – Research Analyst www.choiceindia.com
Bulk Deal
Corporate Action / Result Calendar
SEBI Certified – Research Analyst www.choiceindia.com
Morning Tea
02nd Sept 2015
Security in Ban
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Corporate Action:
Gujarat Alkalies and Chemicals Limited; Annual General Meeting/ Dividend - Rs 4.50/- Per Share.
Hindustan Petroleum Corporation Limited; Annual General Meeting/ Dividend - Rs 24.50/- Per Share.
Aditya Birla Nuvo Limited; Dividend - Rs 7/- Per Share.
LG Balakrishnan & Bros Limited; Annual General Meeting/Dividend - Rs 3.80 Per Share.
The Phoenix Mills Limited; Annual General Meeting/ Dividend - Rs 2.20 Per Share.
Minda Corporation Limited; Annual General Meeting / Dividend Re 0.20/- Per Share.
Maithan Alloys Limited; Annual General Meeting/ Dividend - Rs 2/- Per Share.
Asian Hotels (West) Limited; Annual General Meeting/ Dividend - Re 1/- Per Share/ E-Voting.
T T Limited; Annual General Meeting/Dividend - Re 1/- Per Share.
Saksoft Limited; Annual General Meeting/ Dividend - Rs 2.50/- Per Share.
Sr.No Deal Date Security Code Security Name Client Name Deal Type Quantity Price
1 1/9/2015 526735 EXCAST TANNA TUSHAR HIRALAL S 796,200 6.05
2 1/9/2015 526735 EXCAST BP FINTRADE PRIVATE LIMITED B 526,718 6.00
3 1/9/2015 526735 EXCAST ANS PRIVATE LIMITED B 498,383 6.22
4 1/9/2015 538295 KAUSAMBI AMITKUMAR RAMESHCHANDRA RANA B 464,501 9.59
5 1/9/2015 538295 KAUSAMBI AMITKUMAR RAMESHCHANDRA RANA S 462,921 9.58
6 1/9/2015 526735 EXCAST SUNIL JAYANTILAL BHATT S 380,938 5.98
7 1/9/2015 526735 EXCAST VIRBHADRASINH JADEJA S 380,000 5.99
8 1/9/2015 526735 EXCAST PAYAL JAYESHBHAI MADIYAR S 350,000 5.98
9 42013 526735 EXCAST AMIT PALA S 350,000 5.98
10 1/9/2015 526735 EXCAST AMIT PALA S 347,103 5.98

3. SEBI Certified – Research Analyst www.choiceindia.com
Contact Us
www.choiceindia.com
www.choiceindia.comcustomercare@choiceindia.com
Disclaimer
This is solely for information of clients of Choice Broking and does not construe to be an investment advice. It is also not intended as an offer or solicitation for the purchase and sale of any financial
instruments. Any action taken by you on the basis of the information contained herein is your responsibility alone and Choice Broking its subsidiaries or its employees or associates will not be liable in
any manner for the consequences of such action taken by you. We have exercised due diligence in checking the correctness and authenticity of the information contained in this recommendation, but
Choice Broking or any of its subsidiaries or associates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the
information contained in this recommendation or any action taken on basis of this information. Technical analysis studies market psychology, price patterns and volume levels. It is used to forecast
future price and market movements. Technical analysis is complementary to fundamental analysis and news sources. The recommendations issued herewith might be contrary to recommendations
issued by Choice Broking in the company research undertaken as the recommendations stated in this report is derived purely from technical analysis. Choice Broking has based this document on
information obtained from sources it believes to be reliable but which it has not independently verified; Choice Broking makes no guarantee, representation or warranty and accepts no responsibility
or liability as to its accuracy or completeness. The opinions contained within the report are based upon publicly available information at the time of publication and are subject to change without
notice. The information and any disclosures provided herein are in summary form and have been prepared for informational purposes. The recommendations and suggested price levels are intended
purely for trading purposes. The recommendations are valid for the day of the report however trading trends and volumes might vary substantially on an intraday basis and the recommendations may
be subject to change. The information and any disclosures provided herein may be considered confidential. Any use, distribution, modification, copying, forwarding or disclosure by any person is
strictly prohibited. The information and any disclosures provided herein do not constitute a solicitation or offer to purchase or sell any security or other financial product or instrument. The current
performance may be unaudited. Past performance does not guarantee future returns. There can be no assurance that investments will achieve any targeted rates of return, and there is no guarantee
against the loss of your entire investment.
POTENTIAL CONFLICT OF INTEREST DISCLOSURE (as on date of report) Disclosure of interest statement – • Analyst interest of the stock /Instrument(s): - No. • Firm interest of the stock /
Instrument (s): - No.
SEBI Certified – Research Analyst www.choiceindia.com
Research Team
Mr. Sumeet Bagadia Associate Director
Kunal Parmar Research Associate
Chandrakant Maske Research Associate
Ritesh Patel Research Associate
Amit Pathania Research Associate
Vikas Chaudhari Research Associate
Rajnath Yadav Research Associate
Satish Kumar Research Associate
Morning Tea
02nd Sept 2015
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website